8-KMaterial AgreementsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Material Agreement (Sep 21, 2007)

Filed September 21, 2007For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K report on September 20, 2007, detailing a material definitive agreement. Specifically, the company's affiliate entered into the Ninth Amendment to a Receivables Purchase Agreement dated December 21, 2000. This amendment primarily serves to extend the maturity date of the existing agreement from its original term to September 16, 2008. This extension of the receivables purchase agreement is a positive development for investors as it provides continued access to financing through its securitization program. Extending the maturity date suggests that the company is proactively managing its liquidity and capital structure, ensuring a stable funding source for its operations and growth initiatives through at least mid-2008. Investors should view this as a sign of financial stability and operational continuity.

Key Highlights

  • 1Edwards Lifesciences Corporation (EW) filed an 8-K on September 20, 2007, reporting a material definitive agreement.
  • 2An affiliate of the company entered into the Ninth Amendment to its Receivables Purchase Agreement.
  • 3The Receivables Purchase Agreement was originally dated December 21, 2000.
  • 4The primary purpose of the Ninth Amendment is to extend the maturity date of the agreement.
  • 5The new maturity date for the Receivables Purchase Agreement is September 16, 2008.
  • 6This amendment ensures continued access to funding through their securitization program.

Frequently Asked Questions

The main purpose of this 8-K filing is to report a material definitive agreement, specifically the Ninth Amendment to Edwards Lifesciences' Receivables Purchase Agreement, which extends its maturity date.

A Receivables Purchase Agreement (RPA) is a financing arrangement where a company sells its accounts receivable (money owed by customers) to a third party (often a bank or special purpose entity) at a discount to raise cash. This helps manage cash flow and liquidity.

Extending the maturity date to September 16, 2008, indicates that Edwards Lifesciences has secured continued access to this source of funding for an additional period. This provides financial stability and flexibility for the company's operations and strategic initiatives.

The filing primarily concerns the extension of an existing agreement, not the creation of new material financial obligations beyond the terms already established in the original agreement and its previous amendments. The key impact is the extended availability of financing.